New Financial Services Platform Will Reduce China's Biomedical Financing Bottleneck
This article was originally published in PharmAsia News
The Shenzhen Nanshan Science and Technology Institute and China Construction Bank's Shenzhen branch recently signed an agreement to jointly establish a biomedical financial services platform
You may also be interested in...
T-knife, a developer of T-cell receptors intended for T-cell therapy in solid tumor cancers, says the series A gives its development program three years of financial runway.
A selection of articles you might have missed from July 2020, including exclusive interviews with industry leaders and a review of Q2 financing statistics.
Despite leading multinational pharma firms including AstraZeneca again delivering double-digit growth in China, the impact of coronavirus and an expanding volume-based purchasing scheme begin to surface.